Cypher’s Impact On Regulatory, Reimbursement Landscape
This article was originally published in The Gray Sheet
Executive Summary
During its rise and fall as the first device on the “blockbuster” drug-eluting stent market, Cordis' Cypher sirolimus-eluting coronary stent helped break new ground on both regulatory and reimbursement fronts.